Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUS NASDAQ:AMAG NASDAQ:ARCT NASDAQ:AVDL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$3.17-3.4%$3.32$2.71▼$4.73$607.14M1.2956,829 shs1.12 million shsAMAGAMAG Pharmaceuticals$13.75$13.74$4.41▼$13.80$477.47M0.89950,664 shsN/AARCTArcturus Therapeutics$13.78-4.8%$12.60$8.04▼$25.88$373.73M2.27417,520 shs251,217 shsAVDLAvadel Pharmaceuticals$9.61-1.6%$9.28$6.38▼$17.30$929.66M1.421.23 million shs760,168 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma0.00%-2.01%-11.45%+0.96%-7.04%AMAGAMAG Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ARCTArcturus Therapeutics0.00%+1.06%+9.02%+42.06%-36.59%AVDLAvadel Pharmaceuticals0.00%+7.68%+2.89%+25.13%-40.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABUSArbutus Biopharma2.1391 of 5 stars3.50.00.00.02.72.50.6AMAGAMAG PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AARCTArcturus Therapeutics1.7387 of 5 stars3.60.00.00.01.22.50.6AVDLAvadel Pharmaceuticals1.8046 of 5 stars3.51.00.00.01.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 3.00Buy$5.5073.50% UpsideAMAGAMAG Pharmaceuticals 0.00N/AN/AN/AARCTArcturus Therapeutics 3.11Buy$54.00291.87% UpsideAVDLAvadel Pharmaceuticals 3.00Buy$18.1789.04% UpsideCurrent Analyst Ratings BreakdownLatest AVDL, AMAG, ARCT, and ABUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform7/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$32.00 ➝ $35.005/28/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$32.005/14/2025ARCTArcturus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$50.00 ➝ $45.005/13/2025ARCTArcturus TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/13/2025ARCTArcturus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$68.00 ➝ $66.005/8/2025AVDLAvadel PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$6.40M94.82N/AN/A$0.51 per share6.22AMAGAMAG Pharmaceuticals$327.75M1.46N/AN/A$7.37 per share1.87ARCTArcturus Therapeutics$152.31M2.45N/AN/A$8.90 per share1.55AVDLAvadel Pharmaceuticals$169.12M5.50N/AN/A$0.77 per share12.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$69.92M-$0.41N/AN/AN/A-1,196.64%-75.51%-55.81%8/7/2025 (Estimated)AMAGAMAG Pharmaceuticals-$466.46M-$6.88N/A76.39N/A-74.93%-16.92%-5.96%N/AARCTArcturus Therapeutics-$80.94M-$2.53N/AN/AN/A-47.47%-27.41%-19.01%8/4/2025 (Estimated)AVDLAvadel Pharmaceuticals-$48.83M-$0.27N/A160.17N/A-13.58%-36.07%-16.30%8/6/2025 (Estimated)Latest AVDL, AMAG, ARCT, and ABUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ABUSArbutus Biopharma-$0.02N/AN/AN/AN/AN/A8/4/2025Q2 2025ARCTArcturus Therapeutics-$1.11N/AN/AN/A$17.64 millionN/A5/14/2025Q1 2025ABUSArbutus Biopharma-$0.09-$0.13-$0.04-$0.13$2.54 million$1.76 million5/12/2025Q1 2025ARCTArcturus Therapeutics-$1.58-$0.52+$1.06-$0.52$25.64 million$29.38 million5/7/2025Q1 2025AVDLAvadel Pharmaceuticals-$0.07-$0.05+$0.02-$0.05$50.57 million$52.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/AAMAGAMAG PharmaceuticalsN/AN/AN/AN/AN/AARCTArcturus TherapeuticsN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus Biopharma0.046.016.01AMAGAMAG Pharmaceuticals1.131.751.45ARCTArcturus Therapeutics0.065.645.64AVDLAvadel PharmaceuticalsN/A2.732.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%AMAGAMAG PharmaceuticalsN/AARCTArcturus Therapeutics94.54%AVDLAvadel Pharmaceuticals69.19%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma20.30%AMAGAMAG Pharmaceuticals12.73%ARCTArcturus Therapeutics16.60%AVDLAvadel Pharmaceuticals5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90191.53 million152.65 millionOptionableAMAGAMAG Pharmaceuticals44034.73 millionN/AOptionableARCTArcturus Therapeutics18027.12 million22.62 millionOptionableAVDLAvadel Pharmaceuticals7096.74 million91.71 millionOptionableAVDL, AMAG, ARCT, and ABUS HeadlinesRecent News About These CompaniesAvadel Pharmaceuticals (NASDAQ:AVDL) Trading Up 7.4% - Should You Buy?July 9, 2025 | marketbeat.comAvadel Pharmaceuticals PLC. (NASDAQ:AVDL) Shares Bought by Iridian Asset Management LLC CTJuly 9, 2025 | marketbeat.comBullish Avadel Pharmaceuticals Insiders Loaded Up On US$761.7k Of StockJuly 7, 2025 | finance.yahoo.comJazz Pharmaceuticals: I See Big Potential In This Stock As An InvestorJuly 7, 2025 | seekingalpha.comAVDL Avadel Pharmaceuticals plc - Seeking AlphaJuly 5, 2025 | seekingalpha.comAvadel Pharmaceuticals (NASDAQ:AVDL) Share Price Crosses Above Two Hundred Day Moving Average - Here's What HappenedJuly 4, 2025 | marketbeat.comAvadel announces appeals court decision upholding FDA approval of LUMRYZJune 30, 2025 | msn.comASL Strategic Value Fund Issues Open Letter to Avadel ShareholdersJune 30, 2025 | finance.yahoo.comASL pushes for board shakeup at Avadel over handling of sleep drug rolloutJune 30, 2025 | reuters.comAvadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act LitigationJune 30, 2025 | globenewswire.comStocks to Watch: NextEra, Juniper, HPE, SunRunJune 30, 2025 | wsj.comASL Strategic Value Fund targets Avadel board over Lumryz drug mismanagement, WSJ reportsJune 29, 2025 | reuters.comAn investor in the narcolepsy drugmaker Avadel Pharmaceuticals plans to call for shareholders to vote out the company's entire board of directors, ratcheting up pressureJune 29, 2025 | wsj.comAvadel Pharmaceuticals plc (AVDL) - Yahoo FinanceJune 29, 2025 | finance.yahoo.comAvadel Pharmaceuticals PLC. (NASDAQ:AVDL) Receives Consensus Recommendation of "Buy" from AnalystsJune 20, 2025 | marketbeat.comAvadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)June 16, 2025 | globenewswire.comAvadel Pharmaceuticals (NASDAQ:AVDL) Shares Gap Down - Here's WhyJune 16, 2025 | marketbeat.comWall Street Analysts See an 81.61% Upside in Avadel (AVDL): Can the Stock Really Move This High?June 16, 2025 | zacks.comSurging Earnings Estimates Signal Upside for Avadel (AVDL) StockJune 13, 2025 | zacks.comFollowing a 34% decline over last year, recent gains may please Avadel Pharmaceuticals plc (NASDAQ:AVDL) institutional ownersJune 10, 2025 | finance.yahoo.comAvadel Pharmaceuticals Receives Orphan Drug Designation for LUMRYZ in IHJune 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVDL, AMAG, ARCT, and ABUS Company DescriptionsArbutus Biopharma NASDAQ:ABUS$3.17 -0.11 (-3.35%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$3.14 -0.03 (-0.95%) As of 07/11/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.AMAG Pharmaceuticals NASDAQ:AMAGAMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.Arcturus Therapeutics NASDAQ:ARCT$13.78 -0.70 (-4.83%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$14.14 +0.37 (+2.65%) As of 07/11/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Avadel Pharmaceuticals NASDAQ:AVDL$9.61 -0.16 (-1.64%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$9.46 -0.15 (-1.51%) As of 07/11/2025 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
